A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors June 15, 2017 Sponsor Bristol Myers Squibb Protocol Number Bristol Myers Squibb CA017-003 To Learn More Call 201-510-0910
